Jing Zhao

Jing Zhao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

4 March 2020 in Thoracic Cancer
Verified
Journal Article
Open access
PDF file
HLhongge liang
hongge liang
YXYan Xu
Yan Xu
MCMinjiang Chen
Minjiang Chen
WZWei Zhong
Wei Zhong
MWMengzhao Wang
Mengzhao Wang
JZJing Zhao
Jing Zhao
Background: Immunotherapy plays an important role in advanced non‐small cell lung cancer (NSCLC). However, radiological evaluation is challenging due to the potential inflammatory effects of immunotherapy, which can lead to atypical response patterns. Identifying these atypical responses is critical to making treatment decisions and prognostication.Methods: We performed a retrospective analysis of consecutive advanced NSCLC patients treated with immunotherapy (alone or in combination). We collected patients' clinical and pathological data, analyzed the proportion of patients who continued immunotherapy beyond progressive disease (PD) per RECIST 1.1, and compared the differences in response patterns between the RECIST 1.1 and iRECIST criteria.Results: A total of 43 patients treated at the Peking Union Medical College, China from January 2018 to April 2019 were included. Continued immunotherapy beyond PD per RECIST 1.1 was observed in 10 (33.3%, 10/30) patients, of which there were discordant assessments (30%, 3/10) between the RECIST 1.1 and iRECIST, which were evaluated as PD by RECIST 1.1 and immune unconfirmed PD by iRECIST. Among seven patients with immune confirmed PD, one (1/30, 3.3%) had pseudoprogression. Patients who continued immunotherapy beyond PD (n = 10) experienced significantly prolonged overall survival (not reached vs. 8.1 months: hazard ratio, 2.8; 95% confidence interval: 2.7–13.6, P = 0.03) compared with patients who did not continue immunotherapy beyond PD (n = 20).Conclusions: RECIST 1.1 evaluation underestimated the benefit of immunotherapy. Further research is required to optimize iRECIST and establish some criteria for selecting patients who will benefit from continued immunotherapy beyond PD per RECIST 1.1.

Verified
Journal Article
Open access
PDF file
YZYu Zhang
Yu Zhang
YXYan Xu
Yan Xu
WZWei Zhong
Wei Zhong
JZJing Zhao
Jing Zhao
XLXiaoyan Liu
Xiaoyan Liu
MWMengzhao Wang
Mengzhao Wang
Lung cancer, a malignant neoplasm that is globally prevalent and characterized by high incidence and mortality rates, has seen the rise of immune checkpoint inhibitors (ICIs) as a crucial systemic treatment. However, a subset of patients exhibits suboptimal responses to ICIs. Recently, studies revealed the role of vitamin D in inflammation modulation, cell differentiation, and cancer prevention. Vitamin D precisely modulates immune responses and inflammatory states within the tumor microenvironment (TME) by targeting both innate and adaptive immunity. These effects may reduce immune tolerance to ICIs and synergistically enhance their therapeutic efficacy. Here, we review vitamin D metabolism in lung cancer patients, as well as its anti-tumor mechanisms, immune regulation, and the significant promise of vitamin D in lung cancer immunotherapy and adjuvant therapeutic strategies. Further research is imperative to surmount these challenges and fully realize vitamin D’s potential in improving lung cancer immunotherapy outcomes.

5 January 2024 in Cancer Medicine
Verified
Journal Article
Open access
ZWZhaojue Wang
Zhaojue Wang
YWYang Wu
Yang Wu
TLTao Lu
Tao Lu
YXYan Xu
Yan Xu
MCMinjiang Chen
Minjiang Chen
MWMengzhao Wang
Mengzhao Wang
Background: The optimal systemic treatment for pulmonary large‐cell neuroendocrine carcinoma (LCNEC) remains controversial, and recent advances in LCNEC molecular subtype classification have provided potential strategies for assisting in treatment decisions. Our study aimed to investigate the impact of treatment regimens, molecular subtypes and their concordance on clinical outcomes of patients diagnosed with LCNEC.Patients and Methods: All patients diagnosed with advanced pulmonary LCNEC in Peking Union Medical College Hospital (PUMCH) between January 2000 and October 2021 were enrolled in this retrospective study. The tumor samples were collected and sequenced using a tumor‐specific gene panel, while clinical information was retrieved from the medical records system. The survival and therapeutic response were analyzed and compared between different subgroups classified by treatment regimen (SCLC or NSCLC‐based), molecular subtype (type I or II) or the combination.Results: In univariate subgroup analysis categorized only by treatment regimen or molecular subtype, there were no differences identified in DCR, ORR, PFS, or OS. Nevertheless, the group with consistent treatment regimen and molecular subtype exhibited significantly longer OS than that of the inconsistent group (median OS 37.7 vs. 8.3 months; p = 0.046). Particularly, the OS of patients with type II LCNEC treated with SCLC‐based regimen was significantly prolonged than that of others (median 37.7 vs. 10.5 months; p = 0.039).Conclusions: Collectively, our study revealed the clinical outcomes of different treatment regimens for LCNEC patients highly depend on their molecular subtypes, highlighting the need for sequencing‐guided therapy.

20 December 2020
Verified
Journal Article
Open access
TLTao Lu
Tao Lu
QLQiang Li
Qiang Li
LLLan Li
Lan Li
KYKaizhen Yang
Kaizhen Yang
DZDanfei Zhou
Danfei Zhou
JZJing Zhao
Jing Zhao
恶性胸腔积液表皮生长因子受体(epidermal growth factor receptor, EGFR)基因突变检测缺乏病理质控,导致对检测结果解释及指导临床EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitor, TKI)使用造成困惑。因此,提出质控标准,并按此标准进行胸水EGFR突变检测尤为重要。本研究拟回顾性分析按照严格病理质控标准进行的胸水沉渣切片EGFR基因突变检测结果以及据此结果指导EGFR-TKIs治疗的疗效。 回顾性分析中国医学科学院北京协和医院病理科2012年1月-2018年6月收到的胸腔积液标本的患者临床资料,其中具有临床资料相对完整,且按照制定的质控标准进行了胸水沉渣石蜡包埋切片EGFR基因突变检测的患者132例。根据EGFR基因突变检测结果,分为阳性组和阴性组,比较不同组别使用EGFR-TKIs的疗效。 胸腔积液经离心后,沉渣石蜡包埋、切片,HE染色后镜下观察,若肿瘤细胞数目≥100个,即满足病理质控标准,可用于后续EGFR基因突变检测。132例患者中,72例(54.5%)患者胸水中检出EGFR基因突变。72例突变阳性患者中,69例患者使用了EGFR-TKIs。60例EGFR突变阴性患者中,仅15例使用EGFR-TKIs。EGFR突变阳性组的疾病控制率(disease control rate, DCR)为95.8%,中位无疾病进展生存时间(progression-free survival, PFS)为11个月;EGFR突变阴性组的DCR为0%,中位PFS为1个月,两组患者DCR和PFS均有显著差异(P < 0.05)。 经病理质控的胸水沉渣包埋切片可用于EGFR基因突变检测,其结果可指导临床EGFR-TKIs使用。

15 December 2016 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JZJing Zhao
Jing Zhao
RTRui Tian
Rui Tian
TATao An
Tao An
JXJing Xu
Jing Xu
TCTingting Cui
Tingting Cui
ZXZuojun Xu
Zuojun Xu